191 results on '"Criscuolo, Elena"'
Search Results
2. Single spike mutation differentiating XBB.1 and XBB.1.5 enhances SARS-CoV-2 cell-to-cell transmission and facilitates serum-mediated enhancement.
3. Unconventional CD147‐dependent platelet activation elicited by SARS‐CoV‐2 in COVID‐19
4. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
5. Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects
6. The interferon landscape along the respiratory tract impacts the severity of COVID-19
7. A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells
8. Phage Therapy: An Alternative to Antibiotics
9. Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle
10. Editorial: Viral escape of mucosal immunity in sexually transmitted diseases
11. Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge
12. Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols
13. Novel therapeutic investigational strategies to treat severe and disseminated HSV infections suggested by a deeper understanding of in vitro virus entry processes
14. Smallpox vaccination‐elicited antibodies cross‐neutralize 2022‐Monkeypox virus Clade II
15. The initial interplay between HIV and mucosal innate immunity
16. Natural Flavonoid Derivatives Have Pan-Coronavirus Antiviral Activity
17. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy
18. A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation
19. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro
20. Discovering host protein interactions specific for SARS-CoV-2 RNA genome
21. Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2
22. Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
23. Nanopore ReCappable sequencing maps SARS-CoV-2 5′ capping sites and provides new insights into the structure of sgRNAs
24. IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
25. Nanopore ReCappable Sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs
26. Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
27. Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection
28. SARS-CoV-2 Spike Affinity and Dynamics Exclude the Strict Requirement of an Intermediate Host
29. Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection
30. Characterization of a Lineage C.36 SARS-CoV-2 Isolate with Reduced Susceptibility to Neutralization Circulating in Lombardy, Italy
31. Viral Respiratory Pathogens and Lung Injury
32. COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19
33. Epitope Mapping by Epitope Excision, Hydrogen/Deuterium Exchange, and Peptide-Panning Techniques Combined with In Silico Analysis
34. A spatial multi-scale fluorescence microscopy toolbox discloses entry checkpoints of SARS-CoV-2 variants in Vero E6 cells
35. Fast inactivation of SARS-CoV-2 by UV-C and ozone exposure on different materials
36. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro
37. A human stem cell-derived neurosensory-epithelial circuitry on-a-chip to model herpes simplex virus reactivation
38. Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects
39. Poor correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects
40. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
41. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection
42. Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects
43. Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects
44. Next Generation Vaccines for Infectious Diseases
45. JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
46. Role and potential therapeutic use of antibodies against herpetic infections
47. Influenza B-Cells Protective Epitope Characterization: A Passkey for the Rational Design of New Broad-Range Anti-Influenza Vaccines
48. Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjects.
49. Epitope Mapping by Epitope Excision, Hydrogen/Deuterium Exchange, and Peptide-Panning Techniques Combined with In Silico Analysis
50. Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.